Jump to content
  • History of the RRDi


    There was a post at a Yahoo group in  November 23, 2002 that started the idea of making a non profit organization for rosacea sufferers to collaborate together. 

    The Rosacea Research & Development Institute began as an idea by the founder, Brady Barrows, on November 23, 2002 when he founded the following yahoo group:

    health.groups.yahoo.com/group/international-rosacea-society

    The above yahoo group was changed on July 24, 2004 to:

    health.groups.yahoo.com/group/irosacea

    And then later changed on February 14, 2005 to this yahoo group:

    health.groups.yahoo.com/group/rosacea-research

    The above yahoo group was deleted June 7, 2006 since the private forum for corporate members began in April/May 2006. Since then, Yahoo Groups has been removed from the internet. 

    A need for a non-profit organization that heard the voice of rosaceans suffering from this disease was seen early on and discussion continues to this day. Upon moving to Hawaii the founder discovered that forming a non-profit organization in this state would be simpler than in other states and applied for approval as a non-profit corporation. A Charter was set up. The non profit recognition was approved on June 7, 2004 by the State of Hawaii and after a lengthy period, tax-exempt approval as a 501 (c) (3) non profit organization was obtained by the IRS in January 2006 and recognition was effective back to June 7, 2004. This process took over a year and a half. More details of all this are written in the article Why Form Another Non Profit Organization For Rosacea?

    The Board of Directors were chosen by the corporation members and the officers were appointed in January 2005. More board members were added in 2006 and later.

    The web site is constantly being improved by volunteers. Volunteers are seeking funding and you can join us to seek corporate donations, seek grants, or find the best minds to join the RRDi MAC, the only medical advisory committee volunteering to find a cure for rosacea, listen to corporate RRDi members' concerns and advise the board of directors on the direction the RRDi should go. Several private member forums were experimented which have not proven popular. For a number of years the RRDi recommended Warren Stuart's www.rosaceagroup.org as the public forum and volunteers have made the private forum for corporate members on the irosacea.org web site. To use the public forum you must join the RRDi. This public corporate member forum is where decisions are discussed. The public forum can be found at this url:

    http://irosacea.org/forums

    Steve Andreessen spent many volunteer hours on not only the above IPB forum (now called Invision Community)  but also our web site. Warren Stuart has also spent many hours volunteering on the web site as well. Under Warren's direction we purchased the Invision Power Services forum (now called Invision Community). Sadly, Warren Stuart passed away. David Pascoe took over Warren's Rosacea Forum. The focus of the RRDi for years has been to gather together the best minds on rosacea into the RRDi Medical Advisory Committee, gathering volunteers to raise public awareness of the RRDi in the Public Relations Committee and to increase RRDi membership, and finally to increase funding through volunteer efforts in the Funding Committee by volunteers. You can see the results of all this volunteer effort and you can become part of it by joining with just an email address. You may want to read the Message from the Founder and our post about Anonymity, Transparency and Posting before joining.

    The RRDi has been affiliated with sponsoring Tapatalk since some users prefer using Tapatalk on mobile devices. In 2019 we have sponsored a private Tapatalk Rosaceans Forum



  • Posts

    • Clin Cosmet Investig Dermatol. 2023 Jan 26;16:253-256. doi: 10.2147/CCID.S394754. eCollection 2023. ABSTRACT Minocycline is a tetracycline derivative antibiotic commonly used to treat acne, rosacea, and other inflammatory skin conditions. Taking minocycline risks inducing skin pigmentation. If minocycline-induced hyperpigmentation is not treated, it may take months to years for the symptoms to subside after discontinuation of the drug, or the hyperpigmentation may never disappear completely, which can lead to cosmetic anxiety and affect people's quality of life. Previous treatment options for hyperpigmentation were mainly q-switched nd: YAG, ruby, and alexandrite lasers. This article reports a case of facial hyperpigmentation caused by minocycline using a combination of chemical peel and intense pulsed light in a patient with eosinophilic cellulitis (Wells syndrome) who was taking oral minocycline. This case suggests combining chemical peel and intense pulsed light is an effective treatment option for minocycline-induced hyperpigmentation. PMID:36726812 | PMC:PMC9885878 | DOI:10.2147/CCID.S394754 {url} = URL to article
    • Clin Cosmet Investig Dermatol. 2023 Jan 11;16:71-77. doi: 10.2147/CCID.S391893. eCollection 2023. ABSTRACT PURPOSE: Rosacea is a common facial dermatosis, with flares induced by exposome factors. M89PF containing Vichy mineralizing water, probiotic fractions, hyaluronic acid, niacinamide and tocopherol repairs the skin barrier and reinforces skin defences against exposome factors. This study assessed the benefit of M89PF in subjects with rosacea associated with erythema and sensitive skin during the Covid-19 pandemic using protective face masks. METHODS: M89PF was compared to usual skin care in a randomized, split-face study, for 30 days in subjects with rosacea associated with erythema and sensitive skin. Clinical evaluations included erythema, desquamation, skin tightness, dryness, burning sensation, itching, stinging, stinging test, and local tolerability. Instrument evaluations included erythema, skin hydration and TEWL. Subject satisfaction was also assessed. RESULTS: Erythema significantly improved with M89PF at both time points (p<0.01 at D15, and p<0.001 at D30). Skin sensitivity assessed by the skin stinging test improved significantly (p<0.01) with M89PF at D30, compared to baseline and usual skin care. Skin erythema, tightness, dryness, hydration and TEWL significantly improved (p≤0.05) with M89PF at D15 and D30, versus baseline and the untreated side. Subjects were highly satisfied with M89PF at D15 and D30. Tolerance was very good in all subjects. CONCLUSION: In subjects with rosacea, M89PF significantly reduces erythema, skin tightness, dryness and TEWL, and improves skin hydration and skin sensitivity, even when using protective masks. M89PF is well tolerated and received high satisfaction ratings. CLINICALTRIALSGOV NO: NCT05562661. PMID:36660190 | PMC:PMC9843703 | DOI:10.2147/CCID.S391893 {url} = URL to article
    • Arch Dermatol Res. 2023 Jan 18. doi: 10.1007/s00403-023-02531-7. Online ahead of print. ABSTRACT Patient adherence to medications usually increases with age, however, it can also be impacted by other factors. Accountability is a psychosocial construct that is defined as the expectation for an individual to account for their actions. Accountability may also influence patients' motivation to adhere to their treatments. We assessed the relationship between age and perception of accountability as well as efficacy of interventions to improve accountability in a clinical study of 30 rosacea patients. Accountability was assessed using the validated Accountability Measurement Tool. Interventions to improve accountability included a digital interaction group and a digital skin analysis group. All patients were given ivermectin cream 1% and informed to apply it daily for 3-months. There was a negative association between age and AMT scores in all intervention groups, including the control group. Younger patients have a baseline greater perception of accountability that responded more to our interventions. PMID:36652005 | DOI:10.1007/s00403-023-02531-7 {url} = URL to article
    • JCI Insight. 2023 Jan 12:e151846. doi: 10.1172/jci.insight.151846. Online ahead of print. ABSTRACT Rosacea is a common chronic inflammatory skin disease with a fluctuating course of excessive inflammation and apparent neovascularization. Microbial dysbiosis with high density of B. oleronius and increased activity of kallikrein 5, which cleaves cathelicidin antimicrobial peptide, are key pathogenic triggers in rosacea. However, how these events are linked to the disease remains unknown. Here, we show that type I interferons produced by plasmacytoid dendritic cells represent the pivotal link between dysbiosis, the aberrant immune response, and neovascularization. Compared to other commensal bacteria, B. oleronius is highly susceptible and preferentially killed by cathelicidin antimicrobial peptides leading to enhanced generation of complexes with bacterial DNA. These bacterial DNA-complexes but not DNA-complexes derived from host cells are required for cathelicidin-induced activation of plasmacytoid dendritic cells and type I interferon production. Moreover, kallikrein 5 cleaves cathelicidin into peptides with heightened DNA-binding and type I interferon-inducing capacities. In turn, excessive type I interferon expression drives neoangiogenesis via IL22 induction and upregulation of the IL22 receptor on endothelial cells. These findings unravel a novel pathomechanism, which directly links hallmarks of rosacea to the killing of dysbiotic commensal bacteria with induction of a pathogenic type I interferon-driven and IL22-mediated angiogenesis. PMID:36633910 | DOI:10.1172/jci.insight.151846 {url} = URL to article
    • J Clin Med. 2022 Dec 23;12(1):115. doi: 10.3390/jcm12010115. ABSTRACT Rosacea is a common skin disease that affects about 5% of the general population. Its symptoms include telangiectasia, persistent erythema, burning/stinging sensation, dry skin sensation, and pruritus. It is characterized by a chronic course with frequent exacerbation. It often coexists with anxiety and depression, reducing the quality of life of affected patients. The etiopathogenesis of rosacea is complex and not fully elucidated; hence, there is no causative effective treatment. In this review, we highlight the role of a cosmetologist in the treatment of rosacea and the maintenance of remission. As part of medical treatment, patients are advised to introduce lifestyle changes and use proper skin care; a cosmetologist can help educate patients affected with rosacea, create effective home care programs for skin care, and support them with treatments in beauty salons. Proper skin care is essential, including the use of dermocosmetics, cleansing of the skin, and frequent visits to beauty salons for tailored apparatus procedures. A cosmetologist is more accessible to patients and can help implement healthy daily habits, including skin care and eating habits, as well as support and mediate good communication between the patient and the patient's treating physician, thereby improving compliance and ensuring long-term satisfactory outcomes. PMID:36614915 | DOI:10.3390/jcm12010115 {url} = URL to article
×
×
  • Create New...

Important Information

Terms of Use